Nilotinib
Therapeutic Group
Anti-neoplasticsIndication Dosage
Nilotinib is a medication primarily indicated for the treatment of chronic myeloid leukemia (CML) in adults. Specifically, it is used for individuals with newly diagnosed CML in the chronic phase, as well as those with CML in the accelerated phase or blast crisis who are resistant or intolerant to other therapies. Nilotinib works by targeting specific proteins that contribute to the growth and proliferation of cancer cells, thereby helping to manage the progression of this type of leukemia.
Treatment Of Newly Diagnosed Chronic Myeloid Leukaemia in The Chronic Phase:
- Adult: 300 Mg Twice Daily
Treatment Of Chronic And Accelerated Phase Chronic Myeloid Leukaemia In Patients Who Have Resistance To Or intolerance Of Previous Therapy, Including Imatinib:
- Adult: 400 Mg Twice Daily
Content
- Cap 150mg /200mg: Nilotinib 150mg /200mg.
Pregnancy
Positive Evidence Of Risk: Avoid
Stability
- Protein Kinase Inhibitor Antifibrotics
Contra Indications
- Do Not Use In Patients With Hypokalaemia, Hypomagnaesemia Or Long Qt Syndrome.
Precautions
- Do Not Use In Patients With Hypokalaemia, Hypomagnaesemia Or Long Qt Syndrome.
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Abdominal Pain
- Anorexia
- Arthralgia
- Asthenia
- Bone Pain
- Gi Upset
- Cough
- Dizziness
- Dyspepsia
- Dysphonia
- Dyspnea
- Erythema
- Fatigue
- Flushing
- Headache
- Hyperhidrosis
- Hyperkalaemia
- Hypertension
- Hypomagnesaemia
- Insomnia
- Muscle Spasm
- Oedema
- Palpitation
- Paraesthesia
- Pruritus
- Qt-interval Prolongation
- Rash
- Urticaria
- Vertigo
- Weight Changes
- Alopecia
- Bone-marrow Suppression
- Hepatic Failure (fatal Cases Reported)
- Hepatitis B Reactivation
- Hyperuricaemia
- Nausea
- Oral Mucositis
- Thromboembolism
- Tumourlysis Syndrome
- Vomiting